Is NGS a useful clinical tool for the risk stratification of patients pre-transplant?

During the 64th American Society of Hematology Annual Meeting and Exposition, the AML Hub spoke with Ali Bazarbachi, American University of Beirut, Beirut, LB. We asked, Is next-generation sequencing (NGS) a useful clinical tool for the risk stratification of patients pre-transplant?

Ali Bazarbachi discusses the frequency and impact of pre-transplant somatic co-occurring mutations on clinical outcomes of patients with acute myeloid leukemia undergoing allogenic transplant. Bazarbachi uses data from a retrospective registry-based study conducted by the European Society for Blood and Marrow Transplantation to compare the use of NGS with traditional clinical tools for the different types of acute myeloid leukemia mutations.